Biocon Launches Haselmeierrsquos Insulin Pen In Indiazurich Switzerland November 22 2011haselmeier Has Announced That Biocon One Of Asiarsquos Premier Biotechnology Companies Has Launched Insupenreg In India Under The Terms Of The Agreement Between The Two Companies Biocon Has Worldwide Distribution Rights To Insupenreg For Use With Bioconrsquos Insulin And Insulin Analogues The First Launch Of The Insupenreg Has Taken Place With Bioconrsquos Basalogreg And Insugenreg Insulinsthe Insupenreg Is A Reusable Insulin Pen Based On Haselmeierrsquos Popular Ipen Technology It Is Designed To Be Easy To Use For The Patient And Provide Accurate And Reliable Dosing The Insupenreg Is Available In 3 Attractive Colors And Is Currently Custom Designed For Use With Both Basalogreg And Insugenreg Thus Maximizing Patient Conveniencethe Insupenreg Provides Diabetic Patients An Attractive Pen With Userfriendly Features At An Affordable Cost Haselmeier Is Proud To Work With Biocon A Premier Biotechnology Companiy On This Important Program To Develop And Supply Insupenregand We Look Forward To A Long And Successful Partnershiprdquo Said Volker Wirth Director Business Development Amp Marketing At Haselmeierrakesh Bamzai President Marketing At Biocon Added Ldquoi Am Confident That Insupenreg Will Be A Delight For Patients And A Value Enhancer For All Stakeholdersrdquoabout Haselmeier Gmbhhaselmeier Is A Leading Designer And Manufacturer Of Pen And Autoinjection Systems The Companyrsquos Devices Feature Unique Function Design And Technology And Are Marketed By Leading Pharmaceutical And Biotechnology Companies Around The World For More Information Visit Wwwhaselmeiercomabout Biocon Limitedestablished In 1978 Biocon Limited Bse Code 532523 Nse Id Biocon Isin Id Ine376g01013 Is India39s Largest Biotechnology Company By Revenue The Group Promoted By Ms Kiran Mazumdarshaw Is A Fullyintegrated Innovationdriven Healthcare Enterprise With Strategic Focus On Biopharmaceuticals And Research Services Bioconrsquos Value Chain Traverses The Entire Length Of Discovery Development And Commercialization Of Novel Therapeutics With Successful Initiatives In Clinical Development Bioprocessing And Global Marketing Biocon Delivers Products And Solutions To Partners And Customers In Approximately 75 Countries Across The Globe Many Of These Products Have Usfda And Ema Acceptance Bioconrsquos Robust Product Offering Includes The Worldrsquos First Pichiabased Recombinant Human Insulin Insugenreg And Indiarsquos First Indigenously Produced Monoclonal Antibody Biomabegfrtmwwwbioconcom
